

# **Green Globe International, Inc.**

Incorporating Hempacco Co., Inc. on a fully consolidated basis

*Incorporated in Delaware - November 12, 1999*



**HEMPACCO**  
DISRUPTING TOBACCO

## **Condensed Consolidated Interim Financial Statements**

For the Nine Months Ended

**September 30, 2022**

Statements issued and prepared by Management

**Unaudited**

# **Green Globe International, Inc.**

## **Index to Unaudited Condensed Consolidated Financial Statements**

Condensed Consolidated Balance Sheets at September 30, 2022 and December 31, 2021	<b>F-3</b>
Condensed Consolidated Statements of Operations - for the three months and nine months ended September 30, 2022 and 2021.	<b>F-4</b>
Condensed Consolidated Statement of Stockholders Equity for the three months and nine months ended September 30, 2022 and 2021.	<b>F-5</b>
Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2022 and 2021	<b>F-6</b>
Notes to the Financial Statements	<b>F-7</b>

**Green Globe International, Inc.**  
Incorporating Hempacco Co., Inc. on a fully consolidated basis

**CONDENSED CONSOLIDATED BALANCE SHEETS**  
(Unaudited)

	September 30, 2022	December 31, 2021
<b>ASSETS</b>		
<b>Current Assets</b>		
Cash	\$ 3,037,498	\$ 1,521,027
Accounts receivable	452,461	144,246
Accounts receivable - related parties	443,404	137,297
Loans receivable - related parties	4,375	-
Less: Receivables impairment allowance	(15,829)	-
Inventory at cost less obsolescence allowance	1,791,103	198,936
Deposits & prepayments	998,495	706,273
<b>Total Current Assets</b>	<b>6,713,507</b>	<b>2,707,779</b>
<b>Property and Equipment</b>		
Leasehold improvements	31,431	12,431
Furniture, fixtures and equipment	10,637,704	5,149,306
Accumulated depreciation	(879,876)	(161,441)
<b>Total Property and Equipment</b>	<b>9,809,259</b>	<b>5,000,296</b>
<b>Other Assets</b>		
Operating lease - right of use asset	6,109,130	659,319
Right of use Assets - accumulated amortization	(701,123)	(191,152)
<b>Total Other Assets</b>	<b>5,408,006</b>	<b>468,167</b>
<b>Intangible Assets</b>		
Other intangible assets net of amortization	802,076	209,214
<b>Total Assets</b>	<b>\$ 22,732,849</b>	<b>\$ 8,385,455</b>
<b>LIABILITIES AND STOCKHOLDERS' EQUITY</b>		
<b>Current Liabilities</b>		
Accounts payable & accrued expenses	\$ 623,775	\$ 98,457
Accounts payable - related parties	924,473	162,405
Customer pre-paid invoices & deferred revenue	1,798,072	2,128,393
Convertible promissory notes	1,039,500	900,000
Convertible promissory notes - related parties	350,000	175,000
Accrued interest on long term notes	137,557	37,592
Loans payable - related parties	-	9,600
Equipment loans	23,144	1,482,681
Other short term loans	158,328	168,328
Operating lease - right of use liability - short term portion	712,130	111,077
<b>Total Current Liabilities</b>	<b>5,766,978</b>	<b>5,273,533</b>
<b>Long Term Liabilities</b>		
Right of use liability - straight-line rent rule - deferred rent	81,923	15,226
Right of use liability - long term portion	4,695,876	357,091
<b>Total Long Term Liabilities</b>	<b>4,777,800</b>	<b>372,317</b>
<b>Total Liabilities</b>	<b>10,544,777</b>	<b>5,645,849</b>
<b>Stockholders' Equity</b>		
Preferred stock Series C, \$.0001 par value; 25,000,000,000 shares authorized as of September 30, 2022 and December 31, 2021 respectively. 20,000,002,800 and 20,000,004,200 shares outstanding as of September 30, 2022 and December 31, 2021 respectively.	2,000,000	2,000,000
Participating Preferred stock Series A no par value - the 100 issued and outstanding shares were cancelled on May 21, 2021	-	-
Common stock, \$.0001 par value; 75,000,000,000 shares authorized as of September 30, 2022 and December 31, 2021 respectively. 54,970,251,445 and 54,816,153,814 shares issued, and 54,208,251,445 and 54,226,653,814 outstanding as of September 30, 2022 and December 31, 2021 respectively.	5,497,024	5,481,614
Additional paid in capital	29,343,568	16,121,349
Warrant reserves shares issued	(58,950)	(58,950)
Accumulated deficit	(26,443,915)	(20,855,958)
<b>Total Stockholders' Equity</b>	<b>10,337,727</b>	<b>2,688,055</b>
Non-Controlling Interests	1,850,345	51,551
<b>Total Equity</b>	<b>12,188,072</b>	<b>2,739,606</b>
<b>Total liabilities and Equity</b>	<b>\$ 22,732,849</b>	<b>\$ 8,385,455</b>

The accompanying notes are an integral part of these Consolidated Financial Statements



# Green Globe International, Inc.

Incorporating Hempacco Co., Inc. on a fully consolidated basis

## CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

	For the three months ended september 30, 2022	For the three months ended september 30, 2021	For the nine months ended september 30, 2022	For the nine months ended september 30, 2021
<b>Revenue</b>				
<i>Sale of Materials</i>	\$ 1,754,963	\$ 391,321	\$ 5,622,678	\$ 445,049
<i>Sale of Materials - Related Parties</i>	\$ 16,940	-	22,940	-
<i>Manufacturing and Consulting Services</i>	\$ 211,053	34,900	308,931	64,898
<b>Total Revenue</b>	<u>1,982,955</u>	<u>426,221</u>	<u>5,954,549</u>	<u>509,947</u>
<b>Cost of Goods Sold</b>	<u>\$ 1,992,578</u>	<u>312,893</u>	<u>5,282,280</u>	<u>336,419</u>
<b>Gross Profit / (Loss) from Operations</b>	<u>(9,623)</u>	<u>113,328</u>	<u>672,268</u>	<u>173,528</u>
<b>Expenses</b>				
<i>General &amp; Administrative</i>	1,379,286	379,899	2,914,953	1,068,467
<i>General &amp; Administrative - Related Parties</i>	75,000	-	195,000	-
<i>Sales &amp; Marketing</i>	206,573	38,452	723,219	44,992
<i>Research &amp; Development</i>	-	-	-	-
<b>Total Expenses</b>	<u>1,660,860</u>	<u>418,351</u>	<u>3,833,173</u>	<u>1,113,459</u>
<b>Operating Loss</b>	<u>(1,670,483)</u>	<u>(305,023)</u>	<u>(3,160,905)</u>	<u>(939,931)</u>
<b>Other Income / (Expenses)</b>				
<i>Interest expense - including warrant valuations</i>	(66,542)	68,319	(615,622)	(57,700)
<i>Convertible Note Cancellation &amp; Conversion</i>	-	153,553	-	153,553
<i>Loss on Disposal of Assets</i>	-	-	-	(100,000)
<i>Other Expenses (Net)</i>	(10,076)	(214)	(12,635)	(50,358)
<b>Total Other Expenses</b>	<u>(76,618)</u>	<u>(221,658)</u>	<u>(628,258)</u>	<u>(54,505)</u>
<b>Net Loss</b>	<u>\$ (1,747,101)</u>	<u>\$ (526,681)</u>	<u>\$ (3,789,162)</u>	<u>\$ (994,436)</u>
<i>Net Loss attributable to non-controlling interests</i>	577,485	-	1,027,120	-
<b>Net Loss attributable to common shareholders</b>	<u>\$ (1,169,617)</u>	<u>\$ (526,681)</u>	<u>\$ (2,762,043)</u>	<u>\$ (994,436)</u>

### PER SHARE DATA:

<i>Basic &amp; Dilutive Income / (Loss) per common share</i>	<u>(\$0.00)</u>	<u>(\$0.00)</u>	<u>(\$0.00)</u>	<u>(\$0.00)</u>
<i>Weighted average shares basic and diluted</i>	<u>54,267,191,662</u>	<u>54,151,746,182</u>	<u>54,234,493,375</u>	<u>26,416,074,363</u>

The accompanying notes are an integral part of these financial statements



**Green Globe International, Inc.**

**CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY**  
(Unaudited)

	Preferred Shares	Stock \$ Amt @ Par	Common Shares	Stock \$ Amt @ Par	Additional Paid in Capital GGII & HPCO	APIC Warrant Reserve Shares	Retained Deficit GGII & HPCO	Non-Controlling Interests GGII & HPCO	Stockholders' Equity
Balances - June 30, 2022	20,000,002,800	\$ 2,000,000	54,797,751,445	\$ 5,479,774	\$ 18,430,573	\$ (58,950)	\$ (23,321,630)	\$ 475,162	\$ 3,004,929
Issuance of Shares to officer for services - 8-31-22	-	-	2,500,000	250	9,500	-	-	-	9,750
Hempacoo IPO share issuances - less expenses	-	-	-	-	5,468,814	-	-	-	5,468,814
Hempacoo acquisition of machinery and trademarks	-	-	-	-	4,000,000	-	-	-	4,000,000
Payment of trade payable with Hempacoo shares	-	-	-	-	100,000	-	-	-	100,000
Repayment of equipment loan with Hempacoo shares	-	-	-	-	1,182,681	-	-	-	1,182,681
Boustead cashless warrant exercise - conversion to 54,928 shares	-	-	-	-	55	-	-	-	55
Boustead additional IPO expense due to warrant exercise	-	-	-	-	(55)	-	-	-	(55)
Dutchess Group - professional services in exchange for GGII shares	-	-	20,000,000	2,000	-	-	-	-	2,000
North Equities USA Ltd. - marketing services - for Hempacoo shares	-	-	-	-	100,000	-	-	-	100,000
Peacock lawsuit settlement	-	-	150,000,000	15,000	-	-	-	-	15,000
Hempacoo Joint Venture Partner - additional paid in capital	-	-	-	-	52,000	-	-	-	52,000
Equity attributable to Non-Controlling Interests	-	-	-	-	-	-	(1,952,668)	1,952,668	-
Losses Attributable to Non-Controlling Interests	-	-	-	-	-	-	577,485	(577,485)	-
GGII Net Loss for 3 Month Period ended June 30, 2022:	-	-	-	-	-	-	(1,747,101)	-	(1,747,101)
Balances - September 30, 2022	20,000,002,800	2,000,000	54,970,251,445	5,497,024	29,343,568	(58,950)	(26,443,915)	1,850,346	12,188,072
Balances - December 31, 2021	20,000,004,200	\$ 2,000,000	54,816,153,814	\$ 5,481,614	\$ 16,121,349	\$ (58,950)	\$ (20,855,958)	\$ 51,551	\$ 2,739,606
Issuance of shares to officer for services - 2-28-22 and 6-27-22	-	-	5,000,000	500	12,500	-	-	-	13,000
Conversion of Preference Shares to Common Shares	(1,400)	-	1,700,591	170	(170)	-	-	-	-
Conversion of Hempacoo Promissory Note and accrued interest	-	-	-	-	56,592	-	-	-	56,592
Additional paid-in capital for asset contribution to Green Star Labs	-	-	-	-	1,463,452	-	-	-	1,463,452
Creation of warrant valuation expense by Hempacoo	-	-	-	-	437,375	-	-	-	437,375
Shares submitted for cancellation by order of the SEC	-	-	(25,102,960)	(2,510)	-	-	-	-	(2,510)
Hempacoo Pre-IPO 2 share issuances - less expenses	-	-	-	-	339,475	-	-	-	339,475
Non-controlling interest in equity	-	-	-	-	-	-	(873,246)	873,246	-
Non-controlling interest in earnings	-	-	-	-	-	-	449,635	(449,635)	-
Issuance of shares to officer for services - 8-31-22	-	-	2,500,000	250	9,500	-	-	-	9,750
Hempacoo IPO share issuances - less expenses	-	-	-	-	5,468,814	-	-	-	5,468,814
Acquisition of machinery and trademarks	-	-	-	-	4,000,000	-	-	-	4,000,000
Payment of trade payable with Hempacoo shares	-	-	-	-	100,000	-	-	-	100,000
Repayment of equipment loan with Hempacoo shares	-	-	-	-	1,182,681	-	-	-	1,182,681
Boustead cashless warrant exercise - conversion to 54,928 shares	-	-	-	-	55	-	-	-	55
Boustead additional IPO expense due to warrant exercise	-	-	-	-	(55)	-	-	-	(55)
Dutchess Group - professional services in exchange for GGII shares	-	-	20,000,000	2,000	-	-	-	-	2,000
North Equities USA Ltd. - marketing services - for Hempacoo shares	-	-	-	-	100,000	-	-	-	100,000
Peacock lawsuit settlement	-	-	150,000,000	15,000	-	-	-	-	15,000
Hempacoo Joint Venture Partner - additional paid in capital	-	-	-	-	52,000	-	-	-	52,000
Non-controlling interest in equity	-	-	-	-	-	-	(1,952,668)	1,952,668	-
Non-controlling interest in earnings	-	-	-	-	-	-	577,485	(577,485)	-
Net Loss for nine months ended September 30, 2022:	-	-	-	-	-	-	(3,789,162)	-	(3,789,162)
Balances - September 30, 2022	20,000,002,800	2,000,000	54,970,251,445	5,497,024	29,343,568	(58,950)	(26,443,915)	1,850,346	12,188,072

Balances - June 30, 2021	20,000,006,300	\$ 2,000,001	54,017,148,356	\$ 5,401,714	\$ 13,138,683	\$ -	\$ (13,546,248)	\$ -	\$ 6,994,150
UST Mexico - conversion of preference shares plus interest to common	-	-	-	-	-	-	-	-	(0)
Adjustment to accumulated deficit as of 12-31-2020	-	-	-	-	-	-	(1,610)	-	(1,610)
Loss of Goodwill on Consolidation with Hempacoo - June 9, 2021	-	-	-	-	-	-	(4,286,889)	-	(4,286,889)
Transfer Loss of Goodwill on Consolidation with Hempacoo	-	-	-	-	-	-	-	-	-
Cancellation of 100 Preferred Shares Series A on Merger	(100)	-	-	-	-	-	-	-	-
Fischer Notes settlement	-	-	200,000,000	20,000	-	-	-	-	20,000
EMC2 Capital - loan inducement	-	-	1,000,000	100	-	-	-	-	100
First Fire Global - loan inducement	-	-	2,000,000	200	-	-	-	-	200
GGII warrant reserve issues (see note below)	-	-	327,500,000	32,750	-	-	-	-	32,750
Hempacoo Net Losses 6-10-21 through 6-30-21	-	-	-	-	-	-	(35,358)	-	(35,358)
GGII / Hempacoo net loss for the three months ended September 30, 2021:	-	-	-	-	-	-	(541,911)	-	(541,911)
Balances - September 30, 2021	20,000,006,200	2,000,001	54,547,648,356	5,454,764	13,138,683	-	(18,412,016)	-	2,181,432
Balances - December 31, 2020	6,300	\$ 1	3,700,640,356	\$ 370,063	\$ 13,138,683	\$ -	\$ (13,574,937)	\$ -	\$ (66,190)
Adjustment to accumulated deficit as of 12-31-2020	-	-	-	-	-	-	(1,610)	-	(1,610)
Issuance of Shares for Acquisition of Hempacoo - 6-9-2021	-	-	70,312,160,674	7,031,216	-	-	-	-	7,031,216
Loss of Goodwill on Consolidation with Hempacoo - June 9, 2021	-	-	-	-	-	-	(4,286,889)	-	(4,286,889)
Issuance of License Fee to Old Bel Extracts - 6-21-2021	-	-	4,347,876	435	-	-	-	-	435
Hempacoo Net Losses 6-10-21 through 6-30-21	-	-	-	-	-	-	(35,358)	-	(35,358)
Cancellation of 100 Preferred Shares Series A on Merger	(100)	-	-	-	-	-	-	-	-
Fischer Notes settlement	-	-	200,000,000	20,000	-	-	-	-	20,000
EMC2 Capital - loan inducement	-	-	1,000,000	100	-	-	-	-	100
First Fire Global - loan inducement	-	-	2,000,000	200	-	-	-	-	200
GGII warrant reserve issues (see note below)	-	-	327,500,000	32,750	-	-	-	-	32,750
GGII / Hempacoo net loss for the nine months ended September 30, 2021:	-	-	(20,000,000,000)	(2,000,000)	-	-	(513,222)	-	(513,222)
UST Mexico - Conversion of Common to Pref - 6-27-2021	20,000,000,000	2,000,000	-	-	-	-	-	-	-
Balances - September 30, 2021	20,000,006,200	2,000,001	54,547,648,356	5,454,764	13,138,683	-	(18,412,016)	-	2,181,432

Issued as Reserve for Warrants - NOT OUTSTANDING	
EMC2 Capital	65,500,000 \$ 6,550
First Fire Global	131,000,000 \$ 13,100
ISI Investments	131,000,000 \$ 13,100
MacRab LLC	65,500,000 \$ 6,550
LGH Investments	65,500,000 \$ 6,550
Mast Hill	131,000,000 \$ 13,100
	589,500,000 \$ 58,950
Issued and Outstanding:	(589,500,000)

The accompanying notes are an integral part of these financial statements



**Green Globe International, Inc.**  
Incorporating Hempacco Co., Inc. on a fully consolidated basis  
**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS**  
(Unaudited)

	For the nine Months Ended September 30, 2022	For the nine Months Ended September 30, 2021
<b>CASH FLOWS FROM OPERATING ACTIVITIES</b>		
Net Loss	\$ (3,789,162)	\$ (1,338,315)
Adjustments to reconcile net loss to net cash used in operating activities:		
Depreciation and amortization	381,023	73,039
Non-cash adjustment to promissory note principal	14,500	-
Non-cash warrant valuation expense	437,375	180,296
Convertible note interest converted into common shares	6,592	-
Stock issued for promissory note conversion and miscellaneous services	2,000	53,484
Loss on disposal of assets	10,690	100,000
Stock based compensation	122,750	100,000
Settlement of lawsuit by issuance of common shares	15,000	-
Common shares submitted for cancellation by order of the SEC	(2,510)	-
Changes in Operating Assets and Liabilities		
Receivables	(288,475)	(221,071)
Related party receivables and loans	(255,615)	-
Prepays	(292,222)	(1,382)
Inventories	(1,592,168)	(78,027)
Accounts payable	576,101	38,260
Related party accounts payable	762,069	103,817
Accrued liabilities	215,880	(32,409)
Deferred revenues	(330,321)	(81,096)
Net Cash Used In Operating Activities:	(4,006,494)	(1,103,404)
<b>CASH FLOWS FROM INVESTING ACTIVITIES:</b>		
Purchase of property and equipment	(193,653)	(18,901)
Franchise fees and licenses related to joint venture	(152,609)	-
Proceeds from disposal of equipment	40,000	-
Net Cash Used in Investing Activities:	(306,262)	(18,901)
<b>CASH FLOWS FROM FINANCING ACTIVITIES:</b>		
Proceeds from other short term loans	0	83,328
Installment payments against equipment loans	(310,681)	-
Advances from (repayments to) related parties	229,621	-
Proceeds from convertible notes payable	-	1,150,000
Proceeds from related party convertible notes payable	50,000	-
Capital contribution from JV partner	52,000	-
Proceeds from the sale of common stock	6,416,000	-
Offering costs paid in connection with common stock	(607,713)	-
Offering costs paid in connection with sale of common stock	-	-
Net Cash Provided by Financing Activities	5,829,227	1,233,328
CHANGE IN CASH & CASH EQUIVALENTS:	1,516,471	111,023
CASH BALANCE AT BEGINNING OF PERIOD:	1,521,027	500
CASH BALANCE AT END OF PERIOD:	\$ 3,037,498	\$ 111,523
<b>SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:</b>		
Cash Paid for Interest	\$ -	\$ -
Cash Paid for Taxes	\$ 3,635	\$ -
<b>NON-CASH INVESTING AND FINANCING ACTIVITIES:</b>		
Conversion of convertible notes payable and accrued interest to common stock	\$ 56,592	\$ 535,054
Warrants issued to partners and agents	666,150	149,831
Acquisition of plant and equipment by assumption of loan balance from seller	33,825	-
Stock issued for repayment of equipment loan	1,463,452	-
Conversion of convertible preference shares and accrued dividend with common shares	-	4,395,836
Dividend on preferred stock	-	757,479
Initial recording of right of use asset and liability	5,449,811	16,567
Stock issued for settlement of promissory note claim	-	20,000
Stock issued for initial payment to secure patent license	-	435
Stock issued with promissory notes	-	300
Write off investment in Best n' Pet	-	100,000
Payment of related party accrued management fees and rent with common shares	-	525,000

The accompanying notes are an integral part of these financial statements

**GREEN GLOBE INTERNATIONAL, INC.**  
**Notes to the Condensed Consolidated Financial Statements**  
**September 30, 2022 and 2021**  
**(UNAUDITED)**

**NOTE 1 - ORGANIZATION, BUSINESS AND LIQUIDITY**

***Organization and Operations***

Green Globe International, Inc. the ("Company" or "GGII") was formed on November 12, 1999, as a Delaware Corporation.

Hempacco Co., Inc. ("Hempacco") was formed on April 1, 2019, as a Nevada Corporation.

Green Star Labs, Inc. ("Green Star") was formed on January 10, 2022 as a Delaware Corporation.

On April 23, 2021 Hempacco filed a second amendment to its Articles of Incorporation changing its name from The Hempacco Co., Inc. to Hempacco Co., Inc.

Hempacco merged with GGII on May 21, 2021.

An acquisition in which the entity that issues the securities (the legal acquirer) is identified as the acquiree for accounting purposes based on the guidance in ASC 805 paragraph 10-55-11 through 55-15. The entity whose equity interests are acquired (the legal acquiree) must be the acquirer for accounting purposes for the transaction to be considered a reverse acquisition.

On May 21, 2021 (the "Effective Date"), GGII (the Legal Acquirer) completed a share exchange agreement with Hempacco Co. (the Legal Acquiree) which resulted in Hempacco Co. becoming a wholly owned subsidiary of GGII with 100% of the Company shares being owned by GGII.

In accordance with GAAP rule 810, business combinations, the operations of GGII and Hempacco have been consolidated with effect from January 1, 2021, being the beginning of the first accounting quarter that both entities were under common control.

Pursuant to the terms of the share exchange agreement, the Shareholders of Hempacco Co. delivered 18,395,531 shares of common stock to GGII in exchange for 70,312,160,174 shares of GGII common stock which represented 95% of the total issued and outstanding common shares of GGII at the time of the exchange.

Hempacco manufactures and distributes hemp smokables both under its own name and white label products for clients. Hempacco also owns high-tech CBD vending kiosks that it plans to place in retail venues throughout the US, in conjunction with a number of joint venture partners.

Green Star Labs, Inc. manufactures nutraceuticals and cosmetics under its own name brands and also as white label products for clients.

These financial statements are those of Green Globe International, Inc and its subsidiaries.

During 2021, Hempacco entered into the following Joint Ventures:

- a) On or about March 10, 2021, Hempacco entered into a joint venture partnership agreement with VZ Ventures and BX2SD Hospitality, LLC for the sale and marketing of a proprietary brand of smokables containing the D8 infused variety of hemp. Cali Vibes D8, LLC was formed as the entity's business vehicle which will be 50% owned by Hempacco. Hempacco will manage the business operations and accounting, as well as manufacturing the product.
- b) On or about June 22, 2021, the Company entered into a joint venture agreement with Hemp Hop Global, LLC, a Florida based company in the hip hop talent management business and the sale and distribution of branded snack food products. Hemp Hop Global is managed by Rick Ross, an American Rapper and record executive and his business

partner James Lindsay. Hempacco will produce a range of smokable products under the Hemp Hop brand, and Hemp Hop Smokables, LLC was formed as the business entity, of which Hempacco owns 50%.

On December 14, 2021, the Company assigned all of the membership and other equity and ownership interests in Hemp Hop Smokables LLC to Hempacco., Co., Inc. The business launched on or about May 25, 2022.

During the nine months ended September 30, 2022, Hempacco entered into the following Joint Ventures and other significant agreements:

On or about January 20, 2022, Hempacco entered into employment agreements with Sandro Piancone, its CEO, Neville Pearson, the company's CFO, and Jorge Olson, the company's CMO. These agreements supersede and replace The Hempacco's consulting agreements with Mr. Piancone's entity, Strategic Global Partners, Inc., and Mr. Olson's entity, Cube 17, Inc. The key terms of Mr. Piancone's and Mr. Olsen's employment provide for a base salary of \$10,000 per month each, with the potential to earn a performance-based bonus of up to 110% of the annual base salary. Mr. Piancone and Mr. Olsen will also be eligible to participate in any stock or option-based incentive plans that the board of directors may approve in the future. The initial employment period is for three years, with a one-year option to extend being available to the Hempacco. Mr. Pearson's employment agreement with Green Globe International, Inc. remains in place.

On or about January 1, 2022, Hempacco entered into a joint venture agreement with Cheech and Chong's Cannabis Company, a Nevada corporation ("CCCC"), to form a joint venture entity in Nevada, which entity will market and sell Cheech & Chong-branded hemp smokable products. Pursuant to the agreement, the joint venture entity will be owned 50% by each of us and CCCC, we are required to fund \$10,000 to the joint venture entity. As of the date of publication of these financial statements this contribution had not been made, however Hempacco has been producing product inventory at its own expense prior to the official launch of the product in July 2022.

The joint venture agreement calls for Hempacco to manufacture joint venture product and provide accounting, inventory management, staff training, and trade show and marketing services for the joint venture entity, and CCCC is required to provide online marketing and promotion, design and branding, brand management and development, trademark receipt, and sales and distribution services. CCCC is also required to ensure that Cheech Marin and Tommy Chong attend and make appearances at joint venture entity events. As an incentive to enter into this joint venture CCCC was awarded 100,000,000 Green Globe International warrants with a Black-Scholes valuation of \$.00031 per share for a total valuation of \$310,000 on the issue date. This theoretical value was expensed within general and administrative expenses on the statement of operations.

On or about January 19, 2022, Hempacco entered into a joint venture agreement with Stick-It Labs Ltd. ("Stick-It"), an Israeli corporation that manufactures cannabinoid sticks, to develop and sell hemp smokables products in the United States and Mexico utilizing each of the parties' respective expertise. Pursuant to the agreement, the Hempacco is required to fund \$250,000 to the joint venture entity, Stick-It USA, Inc.,

("StickIt US") a newly formed Delaware corporation, and Hempacco will then receive preferred shares entitling us to ?% of distributable profits of the joint venture entity until Hempacco has been repaid \$?, after which the preferred shares will convert into ? shares of common stock of StickIt US. StickIt US will also receive ? shares of Stickit US common stock. Until such time as Hempacco makes its \$? capital contribution, ? shares of Stickit US, representing 100% of the issued and outstanding common shares are owned by the founders and principals of Stickit Labs Ltd.

The agreement grants the right to Stick-It to purchase ? five-year warrants of Green Globe International, Inc. common stock at an exercise price of \$0.01 per share. The warrants are issuable in three tranches, the first 25,000,000 on signing the JV agreement, the second 25,000,000 when StickIt US achieves annual sales revenue in excess of \$5,000,000, and the third tranche will be issued upon StickIt US achieving annual sales revenue in excess of \$10,000,000. The first tranche of 25,000,000 Green Globe International warrants were valued by the Black-Scholes formula at \$0.005095 per share for a total capitalized value of \$127,375. This amount was also expensed within general and administrative expense on the statement of operations.

On January 3, 2022 GGII entered into a joint venture with Curated Nutra LLC, ("Curated Nutra") forming a new corporation, Green Star Labs, Inc. ("Green Star") owned 50% by each party. Green Star will assume the business, operations and assets of



Star Manufacturing, LLC which manufactures CBD nutritional supplements and beauty care consumer goods. Green Star is sub-leasing the 47,544-sf industrial building and cGMP certified lab, located at 4075 Ruffin Road, San Diego, CA 92123 on the same terms as the original lease which expires on July 31, 2024, with one 5-year option to extend. In addition to assuming many white label clients, Green Star will introduce its own product line in the coming months.

The Company's joint venture partners will contribute all plant, property and equipment plus tenant improvements, in exchange for a 50% interest in the joint venture. The Company will operate and manage the business, and will assuming all operating expenses including the lease payments and the employee payroll with effect from January 3, 2022.

As an incentive to enter into this joint venture, Curated Nutra was awarded 100,000,000 Green Globe International warrants with a Black-Scholes valuation of \$.00049 per share for a total valuation of \$49,300 on the issue date. This theoretical value was expensed and represented by the right to use the proprietary marketing information and customer base in accordance with the Company's policy. See note 6 for further information.

On or about June 27, 2022, the Hempacco entered into a letter of intent with Sonora Paper Company, Inc. (SPC) to jointly form a new manufacturing subsidiary that would manufacture hemp wraps, hemp tubes and hemp cones. These are the primary products that we currently supply to our largest customer (see *revenue concentration* in note 2 below) and that we currently purchase from a third-party vendor. This vertical integration strategy is designed to ensure that we have total control of our supply chain and minimize the risks of not being able to satisfy the demand for these products.

Hempacco will own 80% of the new venture. Hempacco's Delaware incorporated subsidiary, The Real Stuff, will be renamed Hempacco Paper Co., Inc. (HPC). Hempacco shall arrange an IMMEX agreement (maquiladora) to set up a manufacturing facility in Tijuana, Mexico.

Hempacco will provide all initial funding needs as well as the physical location of the manufacturing facility. Hempacco will be responsible for day-to-day operations. SPC shall provide know how as well as access to SPC's patented and patent pending products that it currently manufactures in Sonora Mexico. SPC will continue its separate business manufacturing many of the products that HPC will manufacture. HPC and SPC will cooperate to develop new products and services, and both parties have agreed not to undercut or undermine, or in any way interfere with each other's contracts, agreements or respective clients. The preparation of a joint venture contract is in progress, and upon the execution of the contract by both parties, SPC will be issued 20% of the common shares of Hempacco Paper Company, Inc.

On August 29, 2022, Hempacco Co., Inc. entered into an underwriting agreement with Boustead Securities, LLC, as representative (the "Representative") of the underwriters (the "Underwriters") in connection with the initial public offering of Hempacco (the "IPO"). The Underwriting Agreement provides for the offer and sale of 1,000,000 shares of the Hempacco's common stock, par value \$0.01 (the "Common Stock") at a price to the public of \$6.00 per share (the "Offering"). In connection therewith, Hempacco agreed to issue 70,000 warrants to purchase shares of Common Stock, exercisable from September 1, 2022, through August 29, 2027, and initially exercisable at \$9.00 per share subject to adjustment as provided therein (the "Representative's Warrants"). Hempacco also granted the Underwriters an option for a period of 45 days to purchase up to an additional 150,000 shares of Common Stock. The Offering is being made pursuant to a Registration Statement on Form S-1 (File No. 333-263805) (the "Registration Statement"), which was declared effective by the Securities and Exchange Commission on August 29, 2022.

The Underwriting Agreement includes customary representations, warranties and covenants by Hempacco. It also provides that Hempacco will indemnify the Underwriters against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the "Securities Act"), or contribute to payments the Underwriter may be required to make because of any of those liabilities.

On September 1, 2022, the Offering was completed. At the closing, Hempacco sold 1,000,000 shares of Common Stock for total gross proceeds of \$6,000,000, and (ii) issued the Representative's Warrants. After deducting the underwriting commission and expenses, Hempacco received net proceeds of \$5,468,813.

Finally, in connection with the effectiveness of the Registration Statement and the appointment of Miki Stephens as a member of the Board of Directors, effective August 29, 2022, Hempacco entered an independent director agreement (the

“Independent Director Agreement”) with Ms. Stephens, pursuant to which Ms. Stephens would serve as director of the company until removal or resignation, and with compensation terms reserved for future determination by Hempacco and Ms. Stephens.

### ***Going Concern Matters***

. The accompanying financial statements have been prepared on a going concern basis, which assumes the Company will be able to realize its assets and settle its liabilities in the normal course of business for the foreseeable future.

## **NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES**

### ***Basis of Presentation***

The accompanying unaudited Condensed Financial Statements and related notes have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). The unaudited Condensed Consolidated Financial Statements reflect all normal recurring adjustments which, in management’s opinion, are necessary for a fair statement of the Company’s financial position, results of operations and stockholders’ equity and cash flow for interim periods.

These unaudited interim condensed financial statements do not include all of the information required in annual financial statements. Some of the fiscal 2021 comparative figures may have been reclassified to conform to the current period’s presentation.

### ***Principles of Consolidation***

The financial statements include the accounts of the Company and all of its wholly owned subsidiaries. All significant inter-company balances and transactions have been eliminated in consolidation.

Joint Venture entities where the Company owns at least 51% voting control and controls the accounting, administration and financing of the entities will be accounted for under ASC 810-10 which will allow full consolidation of the assets and liabilities into the Company’s balance sheet, with non-controlling interests being calculated and disclosed in the balance sheet and operating statement of the Company. Joint Venture entities where the Company owns less than 51% are evaluated for treatment as variable interest entities. The Company may provide accounting and administration for these entities, may have board of director control, and may provide majority of funding for these entities. Any entities not falling within this criterion will be accounted for under ASC 323-30. These condensed consolidated interim financial statements include the operating results and the assets of two joint venture entities that have been deemed variable interest entities for the period ended June 30, 2022. The non-controlling interests of these ventures have been disclosed on the consolidated balance sheet and income statement.

### ***Use of Estimates***

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Some of these judgments can be subjective and complex, and, consequently, actual results may differ from these estimates.

### ***Revenue Concentration***

Sales to one of Hempacco’s customers made up approximately 81% of Hempacco’s revenues for the nine months ended September 30, 2022, and the balance receivable from this customer at September 30, 2022 represents approximately 49% of the total accounts receivable balances of \$449,249 as of that date. We do not have a binding purchase agreement with this customer, and if we were to lose this customer, our revenues would significantly decline, and our business might be harmed.

### ***Basic and Diluted Net Loss per Common Share***

Pursuant to ASC 260, “Earnings Per Share,” basic net income and net loss per share are computed by dividing the net income and net loss by the weighted average number of common shares outstanding. Diluted net income and net loss per share is the

**Green Globe International, Inc.**  
**Notes to consolidated financial statements**

**NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (continued)**

same as basic net income and net loss per share when their inclusion would have an anti-dilutive effect due to our continuing net losses.

For the nine months ended September 30, 2022 and 2021, the following outstanding dilutive securities were excluded from the computation of diluted net loss per share as the result of the computation was anti-dilutive.

	September 30 2022 (Shares)	September 30 2021 (Shares)
<b>Promissory Notes convertible to shares</b>	1,375,000	1,075,000
<b>TOTAL</b>	<u>1,375,000</u>	<u>1,075,000</u>

***Fair Value of Financial Instruments***

FASB ASC 820, *Fair Value Measurements and Disclosures* (“ASC 820”) establishes a framework for all fair value measurements and expands disclosures related to fair value measurement and developments. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.

ASC 820 requires that assets and liabilities measured at fair value are classified and disclosed in one of the following three categories:

- Level 1—Quoted market prices for identical assets or liabilities in active markets or observable inputs.
- Level 2—Significant other observable inputs that can be corroborated by observable market data; and
- Level 3—Significant unobservable inputs that cannot be corroborated by observable market data.

The carrying amounts of cash, accounts receivable, accounts receivable – related parties, inventory, deposits and prepayments, accounts payable and accrued liabilities, accounts payable – related parties, customer pre-paid invoices & deposits, other short-term liabilities – equipment loan, operating lease – right of use liability – short term portion approximate fair value because of the short-term nature of these items.

***Share-Based Compensation***

The Company accounts for share-based compensation in accordance with ASC 718, “Compensation – Stock Compensation,” which requires all such compensation to employees and non-employees, including the grant of employee stock options, to be calculated based on its fair value at the measurement date (generally the grant date), and recognized in the statement of operations over the requisite service period or as vesting occurs.

The Company recorded \$22,750 and \$0 in share-based compensation expense for the nine months ended September 30, 2022 and 2021, respectively, pursuant to a contract with the Company’s Chief Financial Officer.

***Advertising and Marketing Costs***

Costs associated with advertising and marketing promotions are expensed as incurred. Advertising and marketing expense was \$723,219 and \$44,992 for the nine months ended September 30, 2022 and 2021, respectively.



## ***Revenue Recognition***

The Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers. The Company generally earns its revenue by supplying goods or providing services under contracts with its customers in two primary revenue streams: manufacturing and commercial product supply and white label development services. The Company measures the revenue from customers based on the consideration specified in its contracts, or the value of the amount invoiced should the initial order be a basic purchase order or emailed order.

The Company recognizes revenue from customers when control of the goods or services are transferred to the customer, generally when products are shipped, at an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods.

Per Company policy, any product that doesn't meet the customer's expectations can be returned within the first 30 days of delivery in exchange for another product or for a full refund. Any product sold through a distributor or retailer must be returned to the original purchase location for any return or exchange. For the nine months ended September 30, 2022 and 2021, the Company has not recorded any reserves on revenue.

The majority of the Company's revenue is derived from sales of branded products to consumers via our direct-to-consumer (DTC) ecommerce website, distributors, and retail and wholesale "white label" business-to-business (B2B) customers.

For larger orders, the Company requires the customer to make a deposit equal to 50% of the invoice or order total which is recorded as customer prepaid invoices and deferred revenue on the balance sheet. When the product is shipped the customer deposit is recorded into revenue. The Company recorded \$1,798,072 and \$2,128,393 in customer pre-paid invoices and deposits for goods ordered but not delivered, as of September 30, 2022 and December 31, 2021, respectively.

In 2019, Hempacco entered into an arrangement with a customer whereby the Hempacco was provided with product from the customer for Hempacco's and the customer's use. Under the arrangement, 50% of the product provided by the customer was to compensate Hempacco for their services for processing and packaging the customers remaining 50% share. The transaction was recorded at the fair market value of the inventory received, which was similar to the cost of the services to which were to be provided with an increase of \$623,375 to inventory and customer deposits. As of September 30, 2022 and December 31, 2021, the customer deposit liability of \$623,375 remained. The Company will defer revenue on customer deposits and record as revenue once product is delivered.

## ***Non-Controlling Interests***

The Company accounts for the non-controlling interests in its subsidiaries and joint ventures in accordance with U.S. GAAP/ASC 805-20. The Company has chosen to record the Minority interests (NCI's) in the equity section of the balance sheet, and on the income statement, the profit or loss attributable to the minority interest will be reported as a separate non-operating line item.

The Company measures its NCI's using the percentage of ownership interest held by the respective NCI's during the accounting period in accordance with ASC 805-20. For the nine months ended September 30, 2022 and the year ended December 31, 2021, the Company reported minority interest in its accumulated losses and its net assets of \$1,850,345 and \$51,551 respectively. Details below.

	September 30	December 31
	2022	2021
<b>Minority interests in accumulated deficit</b>	(1,164,836)	(137,715)
<b>Minority interests in net assets (less intangible assets)</b>	3,015,181	189,266
<b>TOTAL</b>	<u>1,850,345</u>	<u>51,551</u>

In December 2021, Hempacco Co., Inc. issued 1,300,000 common shares at \$1.00 per share to the public in a pre-IPO offering managed by Boustead Investments, LLC. Net proceeds of \$1,027,565 were received by Hempacco after all commission and expenses. See Note 13 below for further details. This public offering by Hempacco Co., Inc. a subsidiary of Green Globe International, Inc. (its publicly traded parent company) is classified as a minority interest in the books of GGII, and is taken into account when calculating the percentage of non-controlling interests of the parent company.

During the nine months ended September 30, 2022, Hempacco recorded another \$16,000 of pre-IPO equity raise expenses which were deducted from the net proceeds previously received. On or about April 7, 2022, Hempacco sold an additional 208,000 shares of common stock at \$2.00 per share to nine investors, eight of which were third parties. Hempacco received gross proceeds of \$416,000, and net proceeds of \$355,475 after payment of commission and expenses to Hempacco's registered broker and the payment of expenses associated with the private offering and the public offering. On September 2, 2022, ???

### ***Recent Accounting Pronouncements***

In December 2019, the Financial Accounting Standards Board (FASB) issued Accounting Standard Update No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (ASU 2019-12), which simplifies the accounting for income taxes. This guidance will be effective for entities for the fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020 on a prospective basis, with early adoption permitted. We adopted the new standard effective January 1, 2021 and do not expect the adoption of this guidance to have a material impact on our financial statements.

In August 2020, the FASB issued ASU 2020-06, ASC Subtopic 470-20 "Debt—Debt with "Conversion and Other Options" and ASC subtopic 815-40 "Hedging—Contracts in Entity's Own Equity". The standard reduced the number of accounting models for convertible debt instruments and convertible preferred stock. Convertible instruments that continue to be subject to separation models are (1) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify for a scope exception from derivative accounting; and, (2) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in capital. The amendments in this update are effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The Company adopted this standard effective January 1, 2021.

The Company has reviewed all other recently issued, but not yet effective, accounting pronouncements and does not believe the future adoption of any such pronouncements may be expected to cause a material impact on our financial statements.

### **NOTE 3 – ACCOUNTS RECEIVABLE**

As of September 30, 2022 and December 31, 2021, accounts receivable consisted of the following:

	September 30 2022	December 31 2021
<b>Accounts receivable</b>	\$ 452,461	\$ 144,246
<b>Accounts receivable - related parties*</b>	445,404	137,297
<b>Allowance for doubtful accounts</b>	(15,829)	-
<b>Total accounts receivable</b>	<u>\$ 882,036</u>	<u>\$ 281,543</u>

\* Due from UST Mexico, Inc. (\$117,094) and Green Star Labs (\$46,808) for Hemp products, Nutraceuticals \$100 and manufacturing services \$52,066

See Note 12 for additional information on related party transactions related to receivables.

#### NOTE 4 – INVENTORY

As of September 30, 2022 and December 31, 2021, inventory, which consists primarily of the Company's raw materials, finished products and packaging is stated at the following amounts:

	September 30 2022	December 31 2021
<b>Finished goods</b>	\$ 446,835	\$ 41,088
<b>Raw materials (Net of obsolescence allowance)</b>	<u>1,344,268</u>	<u>157,848</u>
<b>Total inventory at cost less obsolescence allowance</b>	<u>\$ 1,791,103</u>	<u>\$ 198,936</u>

The Company identified a potential for obsolescence in particular raw materials and provided an allowance for this risk in full in the year ended December 31, 2020 which was recorded within cost of goods sold in the amount of \$623,375. This obsolescence allowance is continually re-evaluated and adjusted as necessary.

#### NOTE 5 - PROPERTY AND EQUIPMENT

See Note 10 for further information concerning the acquisition of kiosks.

As of September 30, 2022 and December 31, 2021, property and equipment consisted of the following:

	September 30 2022	December 31 2021
<b>Production equipment</b>	\$ 6,992,600	\$ 1,463,198
<b>Leasehold improvements</b>	31,431	12,431
<b>Kiosks plus improvements</b>	3,665,104	3,686,107
<b>Less accumulated depreciation</b>	<u>(879,876)</u>	<u>(161,441)</u>
<b>Total property and equipment</b> <b>TOTAL</b>	<u>\$ 9,809,259</u>	<u>\$ 5,000,295</u>

Depreciation expense totaled \$221,276 and \$73,224 for the nine months ended September 30, 2022 and 2021, respectively.

#### NOTE 7 – OPERATING LEASES – RIGHT OF USE ASSETS

The Company entered into a 24-month lease in respect of approximately 457 square feet of office space on September 1, 2021 for a period of 2 years, in Scottsdale, Arizona. A security deposit of \$800 was paid, and the lease contains an option to extend for two further 24-month periods. Base monthly rent (inclusive of two parking spaces) commences at \$850 per month (plus AZ rent taxes) with subsequent defined annual increases. The lease is full-service gross with exception of internet services which are borne by the lessee. At inception of the lease, the Company recorded a right of use asset and liability in the amount of \$16,567. The Company used an effective borrowing rate of 9.32% within the calculation.

Lease expense on the straight-line basis of \$ 775 per month was \$6,975 for the nine months ended September 30, 2022.

Hempacco entered into a 60-month lease to lease approximately 5,000 square feet of office space on January 1, 2020 for a period of 6 years with a related party, an entity controlled by Hempacco's CEO. Approximately 3,000 sf is used as a manufacturing facility with the balance used as corporate offices and storage. There was no security deposit paid, and the lease



carries no optional extension periods. The term of the lease is for six years. At inception of the lease, Hempacco recorded a right of use asset and liability. Hempacco used an effective borrowing rate of 6.232% within the calculation.

Base monthly rent commenced at \$10,000 per month, with subsequent defined annual increases. All operating expenses are born by the lessee. Amounts payable to the related party for rent as of September 30, 2022 and December 31, 2021 were \$0 and \$116,940 respectively. On September 30, 2022 an amount of \$17,752 of prepaid rent was included in the deposits and prepayments account.

Lease expense, on the straight-line basis of \$10,780 per month was \$97,020 for the nine months ended September 30, 2022 and 2021, respectively.

The Company assumed a 63-month lease in respect of a 47,544-sf industrial building in San Diego, as part of the terms of the Green Star Labs, Inc. joint venture. See Note 1 above. Base rental is \$69,102 as of month 33, increasing by 3% on the anniversary date of the lease. The lease expires on July 31, 2024 and there is one 5-year option to extend for a further five years. The Company recorded a right of use asset and liability in the amount of \$5,449,811 representing the net present value of the of remaining lease payments at an incremental borrowing cost ("IBR") of 5.75%. Management is reasonably certain that the lease will be extended for a further five years.

The total lease expense, on the straight-line basis of \$77,473.66 per month was \$697,272 for the nine months ended September 30, 2022.

#### **NOTE 8 – OTHER SHORT-TERM LIABILITIES – EQUIPMENT LOANS**

On December 11, 2019, Hempacco entered into a short-term loan for equipment to use in its production. The terms of the loan were, \$1,500,000 over 18 months with zero interest, which necessitated the calculation of an imputed discount of \$109,627, which was being amortized over 18 months. During the year ended December 31, 2021, Hempacco amortized the remaining discount of \$30,465 to interest expense.

The loan is secured by the equipment, and the lender recently agreed to repayments of \$50,000 per month, interest free, which would take approximately thirty months to retire the loan, assuming no additional paydowns were made by supplying smokable products. On January 6, 2022 the first payment of \$50,000 was made to the lender. Hempacco has been granted forbearance with respect to further loan payments until Hempacco's planned IPO is funded. The note was repaid on September 6, 2022 with a combination of cash and Hempacco common shares (see note 13 below). The balance on the note was \$0 and \$1,482,681 as of September 30, 2022 and December 31, 2021, respectively.

On January 1, 2022 Hempacco, through its subsidiary Hempbox Vending acquired five operational vending kiosks located in Canada. The capital cost of \$33,825 was represented by the outstanding loan balance due to Ascentium Capital which was assumed by Hempacco. The loan balance outstanding as of September 30, 2022 was \$17,804 and is repayable in monthly installments of \$1,780.

In January 2022, the Company assumed control of five vending kiosks located in Canada from the current owner/operator. Hempbox Vending became a subsidiary of Hempacco with effect from January 1, 2022 at which time the assets and the liability were recorded in the books of Hempacco.

The total acquisition cost was \$43,618 paid partly in cash and partly by the assumption of the equipment loan of \$33,825 which amount has been recorded in the books of Hempbox vending as fixed asset additions. The loan balance, due to Ascentium Capital, as of September 30, 2022 was \$23,143 which will be paid in thirteen monthly installments of \$1,780.28 plus monthly insurance premiums of \$368.24.

#### **NOTE 9 – CONVERTIBLE NOTES**

During the year ended December 31, 2021, Hempacco issued twelve convertible promissory notes totaling \$650,000 and warrants to purchase up to 750,000 shares of Hempacco common stock at \$1.00 per share were issued to two related party members of the Board of Directors. Subsequently, as a result of the merger and share exchange agreement of May 21, 2021

between Hempacco and Green Globe International, Inc. these warrants were cancelled and replaced on November 9, 2021 with equivalent warrants to purchase Green Globe common shares. See Note 9 below for additional details.

Individual note holders converted \$511,500 in principle and \$23,552 in accrued interest into 535,052 shares of Hempacco common stock. On May 21, 2021, these shares were exchanged for 2,236,213,775 of GGII's common shares.

On February 17, 2020, Hempacco entered into a financing arrangement with a related party (Jerry Halamuda, a Board of Directors member), to provide working capital. Hempacco received proceeds of \$50,000. An additional 25,000 shares were offered as an inducement which created a beneficial conversion feature of \$25,000, which was charged to interest expense over the term of the loan. The terms of this loan were three months with zero interest rate, maturing on May 17, 2020. On May 17, 2020 Hempacco issued 25,000 shares as an inducement to extend the loan for three months until August 17, 2020. Hempacco incurred an interest expense of \$25,000 in connection with this inducement.

On June 30, 2020, Hempacco repaid \$25,000 of the principal on the note. As of December 31, 2020, the balance on the note was \$25,000. The Note was convertible into common shares on a \$1 for \$1 basis. The Note was converted on May 21, 2021 in the total amount of \$25,000 inclusive of accrued interest for 25,000 Hempacco shares.

On February 16, 2021, Hempacco entered into a financing arrangement with a related party (Dr. Stuart Titus, a Board of Directors member), to provide working capital. Hempacco received proceeds of \$50,000. The terms of this loan were one year and annual interest rate was 8%, maturing on February 15, 2022. The Note was convertible into common shares on a \$1 for \$1 basis. The Note was converted on May 21, 2021 in the total amount of \$51,030 inclusive of accrued interest of \$1,030 for 51,030 Hempacco shares.

On July 23, 2020, Hempacco entered into a financing arrangement to provide working capital. Hempacco received proceeds of \$11,500. The terms of this loan were one year and annual interest rate was 12%, maturing on July 23, 2021. As of December 31, 2020, the balance on the note was \$11,500. In addition, \$590 of interest had been accrued as of December 31, 2020. The Note was convertible into common shares on a \$1 for \$1 basis. The Note was converted on May 21, 2021 in the total amount of \$12,623 inclusive of accrued interest of \$1,123 into 12,623 Hempacco shares.

During May and June 2021, Hempacco entered into financing arrangements to provide working capital. Hempacco received proceeds of \$175,000 from three private investors. The promissory notes carried interest at the rate of between 8% and 12% and mature between May 4, 2022 and October 23, 2022. The Notes automatically convert at 75% of the 30-day average bid price of the obligor common stock (or the public company common stock as the case may be), with the exception of the \$50,000 Taverna 12% Note which converts at \$1.00 per share or the current market price of Hempacco stock. The Notes cannot be converted prior to maturity.

With regard to the \$50,000 convertible note payable to Mario Taverna which matured on May 4, 2022, at a Board of Directors meeting held on June 7, 2022, a resolution was passed approving conversion of the Taverna note plus accrued interest into 56,592 shares of Hempacco common stock at a conversion rate of \$1,00 per share. The shares were issued on June 7, 2022.

Between August and November 2021, the Company issued six 12% promissory notes, totaling \$914,500 to the following lenders:

EFFECTIVE DATE	NAME	AMOUNT
August 18,2021	EMC 2 Capital LLC	\$ 100,000 \$
August 25,2021	First Fire Global Opportunities	214,500
August 26,2021	JSJ Investments, Inc.	200,000
November 1,2021	LGH Investments	100,000
November 10,2021	Macrab LLC	100,000
November 11,2021	Mast Hill Fund, LLC	200,000
		\$ 914,500 \$

On or about March 18, 2022 the Company issued a promissory note to a related party for \$50,000. The note carries an interest rate of 8% and matures on June 18, 2022. The note is secured by 50,000 common shares of Hempacco Co., Inc. On June 18, 2022, the Company and the investor signed Amendment No. 2 to the promissory note extending the maturity date to December 18, 2022.

All the notes mature 12 months from the effective date. An Original Issuer Discount of 10% was deducted from the loan proceeds, a commission of approximately 8% was paid to the broker, J.H. Darbie & Co.

A commitment fee of 1,000,000 common shares of GGII was paid to the lenders in respect of each \$100,000 subscription.

Warrant Agreements accompanied each promissory note, the terms of which can be found in Note 10 below. All warrants are valued using the Black-Scholes formula. Warrants issued in connection with a promissory note are capitalized and amortized over the life of the loan. The value of warrants issued as commission are expensed to interest expenses.

Negotiations are on-going for the extension and or repayment / conversion of these notes.

On or about March 18, 2022 the Company issued a promissory note to a related party for \$50,000. The note carries an interest rate of 8% and matures on June 18, 2022. The note is secured by 50,000 common shares of the Company. On June 18, 2022, the Company and the investor signed Amendment No. 1 to the promissory note extending the maturity date to September 18, 2022. Subsequently an Amendment No.2 was executed which extends the maturity date to December 18, 2022.

On or about March 24, 2022, GGII issued a promissory note to a related party for \$100,000. The note carries an interest rate of 8% and matured on May 24, 2022. The note is secured by 100,000 common shares of Hempacco Co., Inc. currently owned by GGII. On or about July 31, 2022 GGII entered into an agreement to extend the maturity date of the note to September 24, 2022. Extended to November 24, 2022

On or about August 25, 2022, GGII issued a promissory note to a related party for \$50,000. The note carries an interest of \$1,000 and matures on October 24, 2022.

## NOTE 10 – WARRANTS

The 750,000 Hempacco warrants issued to Jerry Halamuda and Dr. Stuart Titus in February 2021 were effectively cancelled on May 21, 2021, as a result of the merger and share exchange between Hempacco and Green Globe International, Inc. but not re-issued by Green Globe International, Inc. until November 11, 2021. The total number of replacement warrants issued was 27,173,925 at a strike price of \$.027600 which is the equivalent of 750,000 warrants exercisable at \$1.00 each.

A Black-Scholes valuation discount of \$149,831 was initially recorded. The discount was amortized over the warrant term with the balance remaining at the conversion date being expensed to interest. No further expense was incurred as a result of the modifications of the warrants to GGII warrants. The valuation discount represents the fair market value as derived by using the Black-Scholes Model, which produced an initial valuation of the Hempacco warrants of \$0.4986 per share. The Black-Scholes formula applied to the GGII warrants on June 9, 2021 produced a valuation of \$.0138 per share.

The Black-Scholes model uses the following variables to calculate the value of an option or warrant:

Description	Input Range
a) Price of the Issuer's Security	\$.003 - \$.005
b) Exercise (strike) price of Security	\$.0075 - \$.03
c) Time to Maturity in years	1 to 5 years
d) Annual Risk-Free Rate	2-year T-Bill
e) Annualized Volatility (Beta)	59% - 493%



On August 11, 2021, Hempacco signed an agreement with Boustead Securities, LLC (the “Representative”), which was amended on or about March 18, 2022, effective as of August 11, 2021, with respect to a number of proposed financing transactions, including the initial public offering (“IPO”) of Hempacco’s common stock for which a listing on NASDAQ has been applied for, the private placement of Hempacco securities prior to the IPO (“pre-IPO Financings”), and other financings separate from the IPO or the pre-IPO Financings (each such other financing an “Other Financing”). See Note 13 below for further details.

In addition to the other compensation delineated in the agreement, Hempacco agreed to issue and sell to the Representative (and/or its designees) on the closing date of an IPO or Other Financing as applicable, five-year warrants to purchase shares of Hempacco common stock equal to 7% of the gross offering amount, at an initial exercise price of 150% of the offering price per share in the IPO, or 100% of the offering price in an Other Financing.

On November 23, 2021, Hempacco entered into a Broker Representation Agreement with a Third Party, whereby Broker would receive a commission of 10% on any Net sales brought to Hempacco by their efforts or introductions. In particular, as a bonus for introducing a major client, Broker shall be granted 100,000,000 warrants in Green Globe International, Inc. common shares exercisable at \$0.01 each for a period of three years.

The Black-Scholes valuation of the 100,000,000 warrants as of the contract date is \$0.0018 per share for a total valuation of \$178,317 which has been recorded as a one-time charge to the income statement due to there being no future performance obligations arising from this warrant award.

Between August and November 2021 warrants were issued to nine promissory note lenders (see note 9 above) as follows:

Series A warrants – 81,818,181 exercise price \$.008250  
Series B warrants - 104,347,824 exercise price \$.008625

The warrants expire three years from the effective date of the promissory notes.

The value of the warrant discounts was calculated as \$106,343 and \$122,432 respectively for the Series A and the Series B warrants. The Black-Scholes variable inputs are shown in the table reproduced in this note above.

The Fair Market Value (“FMV”) of the warrants was calculated by multiplying the number of warrants in each loan allocation by the valuation amount produced by the application of the Black-Scholes Model to each warrant allocation.

The warrant discount for each individual loan warrant allocation was calculated by applying the percentage that the FMV of each warrant bears to the total warrant value (FMV plus loan value) to the loan amount. The individual warrant discounts were then summed up to produce the quoted totals.

The warrant discounts are being amortized over the three-year life of the warrants.

J.H. Darbie also received 7,513,047 Series B warrants to purchase GGII common shares as additional compensation.

The value of the Darbie warrants was also calculated using the same methodology as for the lender’s warrants, and produced a valuation of \$15,706 which was expensed as a commission.

## **NOTE 11 – LOAN PAYABLE**

On June 15, 2020, Hempacco entered into a loan agreement with a third party whereby Hempacco received \$85,000. The terms of the loan were for one year, with 0% interest. On January 15, 2021, the lender advanced a further \$83,328 on the same terms. In December 2021 a letter agreement and loan extension were signed by the lender in which it was confirmed that the new maturity date of the loan would be August 15, 2023. The lender also confirmed that \$41,000 of the original loan principal had not yet been extended. As of September 30, 2022 and December 31, 2021, the balance outstanding was \$168,328 and \$168,328 respectively. The same customer advanced a deposit of \$40,000 for the purchase of 10 kiosks which were delivered in February 2022. On July 6, 2022, an additional 2 kiosks were purchased by same customer for \$5,000/each which reduced their loan balance by total of \$10,000.

## NOTE 12 – RELATED PARTY TRANSACTIONS

As of September 30, 2022, the Company and/or Hempacco had entered into the following transactions with Related Parties:

In May 2021, Cube17, Inc., a related party sales and marketing consulting company, converted all outstanding consulting fees earned since the inception of Hempacco in the amount of \$185,000 for 185,000 shares of Hempacco common stock, for \$1 per share. On May 21, 2021, these shares were exchanged for 707,113,562 common shares of Green Globe International, Inc. Consulting expenses of \$90,000 and \$90,000 were recorded for the nine months ended September 30, 2022 and 2021 respectively. Consulting fee balances payable were \$64,000 and \$63,405 as of September 30, 2022 and December 31, 2021, respectively.

In addition, Cube17, Inc., as a founder of Hempacco, converted its 400,000 founders shares into 1,528,997,476 common shares of Green Globe International, Inc.

In May of 2021, Primus Logistics was issued 170,000 common shares of Hempacco as compensation for \$170,000 of accrued and unpaid rent owed at that time by Hempacco from inception. On May 21, 2021, these shares were exchanged for 649,780,985 common shares of the Company. Hempacco CEO, Sandro Piancone, is the 90% owner of Primus Logistics which is considered a related party. Rent Expenses are reported in Note 6 above.

As of September 30, 2022 and December 31, 2021, Hempacco owed Primus Logistics \$0 and \$0 respectively, for routine business transactions. As of September 30, 2022 and December 31, 2021, Primus Logistics had been paid \$17,752 and \$14,764 respectively, in advance, for rent. Sandro Piancone is the 90% owner of Primus Logistics.

In May of 2021, Strategic Global Partners, Inc. was issued 170,000 Hempacco common shares as compensation for \$170,000 worth of consulting services incurred since Hempacco's inception by the CEO, Sandro Piancone, President and Owner of Strategic Global. On May 21, 2021, these shares were exchanged for 649,780,985 common shares of Green Globe International, Inc. Strategic Global Partners is a related party. Consulting expenses of \$90,000 and \$90,000 were recorded for the nine months ended September 30, 2022 and 2021 respectively. Unpaid consulting fee balances of \$78,000 and \$70,000 were outstanding as of September 30, 2022 and December 31, 2021, respectively.

On February 28, 2022, June 27, 2022 and August 31, 2022, the Company's Chief Financial Officer was issued 2,500,000 shares of the Company's common stock pursuant to a Restricted Stock Agreement. The total of 7,500,000 shares were considered an enhancement of base compensation for the nine-month period ended August 31, 2022, as described in the CFO's GGII employment agreement dated September 1, 2021.

As of September 30, 2022 and December 31, 2021, Hempacco owed \$0 and \$29,000 and was owed \$122,352 and \$132,147 respectively, by UST Mexico, Inc. ("UST"). Hempacco sells hemp products to UST and also provides manufacturing consulting services. The value of goods and services provided to UST Mexico, Inc was \$5,546 and \$104,185 for the nine months ended September 30, 2022 and 2021 respectively, and the value of goods and services provided by UST Mexico, Inc. was \$91,956 and \$135,000 for the nine months ended September 30, 2022 and 2021 respectively. UST Mexico, Inc. is a manufacturer of tobacco cigarettes in Mexico and provides consulting services and parts for Hempacco equipment.

UST currently owns 947,200,000 shares of common stock of Green Globe International, Inc., representing 1.74% of the issued and outstanding common stock of the parent company of Hempacco. UST is a related party by virtue of Sandro Piancone's approximately 25% interest in UST.

Lake Como is owned/controlled by Sandro Piancone. This entity is used primarily as a sales company, and sometimes sells products purchased from Hempacco. Hempacco had receivables of \$150 and \$150 due from Lake Como as of September 30, 2022 and December 31, 2021, respectively.

On or about March 1, 2022 the Company entered into a mutual line of credit agreement with its subsidiary, Hempacco Co., Inc. The purpose being to facilitate short-term borrowing needs between the parties on an interest free basis. Advances are subject to repayment within 90-days, with the maximum total of \$500,000 allowed as an outstanding balance within any 90-day period. During the nine months ended September 30, 2022, the Company made and received cash advances of \$417,805 and \$479,150 respectively. As of September 30, 2022 the balance owed to Hempacco by the Company was \$61,345.

Although GGII was a “shell company” at the time of the reverse merger in May, 2021, the fact that Hempacoco, an operating company with business assets and cash flow, had become its wholly owned subsidiary, did, in reality, make GGII also a fully operating company. GGII was maintained as a separate entity to be used as a holding company for potential acquisitions and new business lines. In January 2022 GGII acquired a 50% interest in Green Star Labs, Inc. a nutraceutical manufacturing enterprise in San Diego, California. It took several months before the OTC would consider removing the “shell” status symbol from GGII’s pink open market dashboard page. Shell status was finally removed by the OTC in February 2022.

By the second half of 2021, GGII had developed relationships with lenders, and was able to negotiate a series of loans totaling \$900,000 using convertible promissory notes as security. Thus, GGII was able to provide short term operational funding to its wholly owned subsidiary, Hempacoco Co., Inc.

## **NOTE 13 – STOCKHOLDERS’ EQUITY**

### ***Hempacoco – Series A Preferred Shares***

On May 20, 2021, the Hempacoco’s Board of Directors declared and authorized a 6% common share dividend to Series A Preferred Shareholders. Mexico Franchise Opportunities Fund (“MFOF”) received dividends of \$757,479 which, together with MFOF’s 8,000,000 preferred shares were converted into 8,757,479 shares of Hempacoco common shares.

On May 21, 2021 MFOF exchanged these Hempacoco common shares for 33,473,197,809 shares of GGII common shares.

On September 28, 2021, Hempacoco amended its Articles of Incorporation to increase its authorized Series A Preferred Shares to 50,000,000, and changed its par value to \$0.001. The holder of Hempacoco’s Series A Preferred Stock is entitled to a dividend of 6% payable in common shares, if and when declared by Hempacoco’s Board of Directors. The Series A preferred shares shall not have the right to vote on matters presented to the holders of junior stock.

### ***GGII – Series C Preferred Shares***

On June 27, 2021, the Company, at the request of MFOF converted 20,000,000,000 shares of GGII common stock to 20,000,000,000 shares of Series C Preferred Shares. The Company returned to Treasury the cancellation of 100 Preferred Super Voting shares.

On December 2, 2021, the Company converted 2,000 shares of GGII Preferred Series C to 1,005,458 GGII common stock.

On February 23, 2022, the Company converted 1,400 shares of GGII Preferred Series C to 1,700,591 GGII common stock

As of September 30, 2022 and 2021, the Company had 20,000,002,800 and 20,000,006,200 shares of preferred stock issued and outstanding, respectively.

### ***Common Stock – GGII and Hempacoco***

The Company has authorized 75,000,000,000 common shares with a par value of \$0.0001 per share. Each common share entitles the holder to one vote, in person or proxy, on any matter on which action of the stockholders of the Company is sought. On May 21, 2021, Hempacoco Co. issued 100,000 shares of common stock to a consultant for services rendered. The shares were paid in exchange for software development and IT services related to Hempacoco’s automated CBD kiosks. The Hempacoco common stock was valued at \$100,000 (based upon the contract for services and the agreed upon rates for labor and materials) and was exchanged for 382,224,109 shares of GGII’s common shares.

On June 21, 2021, the Company issued 4,347,826 shares of common stock to Old Belt Extracts in partial payment of a license fee pursuant to a Patent License Agreement dated April 1, 2021 between Hempacoco Co., Inc. and Old Belt Extracts, LLC.

On August 10, 2021 the Company issued 200,000,000 shares of common stock to BB Winks LLC in full settlement of an overdue promissory note that the Company assumed responsibility for as part of the terms of the merger agreement.



Subsequent to year ended December 31, 2020, Hempacco issued convertible promissory notes totaling \$650,000 and warrants to purchase up to 750,000 shares of common stock at \$1 per share. On May 21, 2021, individual note holders converted \$511,500 in principle and \$23,552 in accrued interest into 535,052 shares of Hempacco common stock. On May 21, 2021 these shares were exchanged for approximately 2,045,094,734 of the Company's common shares.

On August 11, 2021, Hempacco signed an agreement with Boustead Securities, LLC (the "Representative"), which was amended on or about March 18, 2022, effective as of August 11, 2021, with respect to a number of proposed financing transactions, including the initial public offering ("IPO") of Hempacco's common stock for which a listing on NASDAQ has been applied for, the private placement of Hempacco's securities prior to the IPO ("pre-IPO Financings"), and other financings separate from the IPO or the pre-IPO Financings (each such other financing an "Other Financing"). A commission of 7% of gross offering proceeds is payable to the Representative, as well as a non-accountable expense allowance of 1% of offering proceeds. In addition, Hempacco will reimburse Boustead for the diligence, legal and road show expenses up to \$205,000.

On September 28, 2021, Hempacco amended its Articles of Incorporation to increase its authorized common shares to 200,000,000, and changed its par value to \$0.001 per share. Each common share entitles the holder to one vote, in person or proxy, on any matter on which action of the stockholders of Hempacco is sought.

On or about December 6, 2021, Hempacco sold 805,541 shares of Hempacco common stock at \$1.00/share to 19 investors, 17 of which were third parties. Neville Pearson, Company CFO, and Dr. Stuart Titus, Company director, purchased 50,000 of the shares for \$50,000, and 100,000 of the shares for \$100,000, respectively. Hempacco received gross proceeds of \$805,541, and net proceeds of \$724,255 after payment of commissions and expenses to Hempacco's registered broker and the payment of expenses associated with the private offering and the Public Offering.

On or about December 14, 2021, the Hempacco sold 494,459 shares of Hempacco common stock at \$1.00/share to 5 investors, 4 of which were third parties. The family trust of Jerry Halamuda, Company director, purchased 50,000 of the shares for \$50,000. Hempacco received gross proceeds of \$494,459, and net proceeds of \$333,309 after payment of commissions and expenses to Hempacco's registered broker and the payment of expenses associated with the private offering and the Public Offering.

On or about April 7, 2022, Hempacco sold 208,000 shares of its common stock at \$2.00 per share to nine accredited investors, eight of which were third parties. Hempacco received gross proceeds of \$416,000, and net proceeds of \$355,475 after payment of commissions and expenses to Hempacco's registered broker, and the payment of expenses associated with the private offering and the public offering.

On April 22, 2022, the Company cancelled 25,102,906 common shares from a former officer who was ordered by the SEC to return shares.

On July 15, 2022, Hempacco issued 2,000,000 shares of Hempacco common stock to Nery's Logistics, Inc. in consideration of the acquisition of two cigarette production equipment lines and multiple tobacco and cigar related trademarks. The machines and trademarks will be used only for hemp related products.

On July 15, 2022, Hempacco also settled two vendor accounts payable balances totaling \$100,000 by the issuance of 50,000 common shares of Hempacco stock.

On September 1, 2022 Hempacco sold 1,000,000 shares of Hempacco common stock at \$6.00 per share to our underwriters pursuant to the IPO and the underwriting agreement with Boustead Securities, LLC. After deducting the underwriting commission and expenses, Hempacco received net proceeds of \$5,468,812.

On September 2, 2022, the Company issued 150,000,000 restricted common shares to Stephen R. Peacock, a former employee of the Company who had filed several lawsuits in an attempt to enforce worthless contracts executed by former directors over a decade ago. After considering the potential additional legal costs that would be incurred in defending this case, despite our confidence of ultimate success, it was decided to remove this annoyance now and settle for a known amount as opposed to an unknown future cost.

On September 6, 2022, Boustead Securities LLC submitted a notice of the exercise of the warrant purchase option to Hempacco pursuant to paragraph 1.3.1 of the Underwriting Agreement. Boustead elected to convert its right to purchase 70,000 common shares of Hempacco stock, using the cashless basis formula, into 54,928 rule 144 shares of Hempacco common stock.

On September 6, 2022, a settlement agreement and mutual release was signed by Hempacco and Titan Agency Management providing for the full repayment of the outstanding equipment loan balance with a cash payment of \$250,000 and the issuance of 266,667 restricted shares of Hempacco common stock.

On September 19, 2022, the Company entered an investor relations consulting agreement with Dutchess Group LLC (“Dutchess”) of San Diego, California, for a period of six months. Dutchess will advise on the production of the Company’s investor relations material, work with the Company on press release writing and editing, and manage social media content. Dutchess will also assist the Company in arranging quarterly shareholder calls, and will disseminate public company information to interested parties selected and approved by the Company. Compensation will be made by the issuance of 100,000,000 rule 144 restricted common shares of the Company, issued in five monthly installments commencing on September 20, 2022.

See Notes 9 and 12 for additional discussion of issuances of common stock.

### **NOTE 13 – COMMITMENTS AND CONTINGENCIES**

On or about October 7, 2022, Hempacco accepted service in a suit filed in the United States District Court for the Southern District of New York by Long Side Ventures LLC, R & T Sports Marketing Inc., Sierra Trading Corp., Taconic Group LLC, KBW Holdings LLC, Robert Huebsch and Ann E. Huebsch, Joseph Camberato, Joseph Crook, Sachin Jamdar, Michael Matilsky, Gerard Scollan, and Daisy Arnold (collectively “Plaintiffs”) against Hempacco Co., Inc., Mexico Franchise Opportunity Fund, LP, Sandro Piancone, Jorge Olson, Neville Pearson, Stuart Titus, Jerry Halamuda, Retail Automated Concepts, Inc. f/k/a Vidbox Mexico Inc., and Vidbox Mexico S.A. De C.V. (collectively “Defendants”) (Case No. 1:22-cv-08152 (ALC)), alleging that (i) Plaintiffs previously received a judgment (the “Judgment”) in a New York state court action (the “State Action”) against Retail Automated Concepts, Inc. (“RAC”) and Vidbox Mexico S.A. De C.V. (“Vidbox Mexico”), for breach of promissory notes issued by RAC to Defendants in 2018 and guaranteed by Vidbox Mexico, and (ii) prior to the filing of the State Action, Defendants fraudulently transferred and commingled assets, specifically 600 retail kiosks, in order to avoid enforcement of the Judgment, with Plaintiffs seeking monetary damages from Defendants. Defendants anticipate filing a motion to dismiss for lack of personal jurisdiction and failure to state a claim, and on or about November 4, 2022, Defendants’ counsel sent the court a letter requesting a pre-trial conference to discuss Defendants’ anticipated motion to dismiss pursuant Rule 2(A) of the court’s Individual Rules of Practice. Defendants intend to defend the matter vigorously.

### **NOTE 14 - SUBSEQUENT EVENTS**

The Company has evaluated subsequent events through November 18, 2022, the date of issuance of these financial statements.

On October 4, 2022, Hempacco issued North Equities USA Ltd. (“North”) 41,494 shares of Hempacco common stock for six months of marketing services to be rendered by North to us, commencing on September 19, 2022, and including content management of our YouTube channel, establishment of a brand ambassador, and social media services.

On October 12, 2022 Hempacco entered a Broadcasting and Billboard Agreement with FMW Media Works LLC (“FMW”) of Hauppauge, New York, for a period of three months. FMW will produce an informative TV show which will discuss Hempacco and its business. Total compensation will be made by the issuance of 63,292 rule 144 restricted common shares of Hempacco.